导痰汤合六君子汤辅助化疗治疗脾虚痰湿型肺癌临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R734.2

基金项目:


Clinical Study on Daotan Tang and Liujunzi Tang in Adjuvant Chemotherapy of Lung Cancer of Spleen Deficiency with Phlegm-Dampness Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察导痰汤合六君子汤辅助化疗治疗脾虚痰湿型肺癌的临床疗效。方法:选取脾虚痰湿型肺癌患者136 例,按随机数字表法分为对照组与研究组各68 例。对照组采取DP 化疗方案,研究组在对照组的基础上联合导痰汤合六君子汤治疗。统计2 组临床疗效、肿瘤控制率、不良反应情况;比较2 组免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)、血清肿瘤标志物[癌坯抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19 的可溶性片段(CYFRA21-1)] 水平变化。结果:研究组总有效率为94.12%,对照组为82.35%,2 组比较,差异有统计学意义(P<0.05)。研究组肿瘤控制率为86.77%,对照组为72.06%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组CD3+、CD4+、CD8+、CD4+/CD8+比较,差异无统计学意义(P>0.05)。治疗后,研究组CD3+、CD4+、CD4+/CD8+水平高于对照组(P<0.05),CD8+水平低于对照组(P<0.05);对照组CD3+、CD4+、CD4+/CD8、CD8+水平治疗前后变化差异无统计学意义(P>0.05)。治疗后,2 组血CEA、CA125、CYFRA21-1 水平较治疗前降低(P<0.05),且研究组各项指标均低于对照组(P<0.05)。研究组肝肾功能损伤、血红蛋白减少、呕吐、腹泻、谷丙转氨酶异常发生率均低于对照组,差异有统计学意义(P<0.05)。结论:导痰汤合六君子汤辅助化疗治疗脾虚痰湿型肺癌疗效确切,可改善患者免疫功能,降低血清CEA、CA125、CYFRA21-1 水平,减少不良反应。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Daotan tang and Liujunzi tang in adjuvant chemotherapy of the lung cancer of spleen deficiency with phlegm- dampness type. Methods: A total of136 patients with the lung cancer of spleen deficiency with phlegm-dampness type were randomly divided into the control group and the study group,68 cases in each group. The control group was treated with DP chemotherapy, and the study group was additionally treated with Daotan Decoction and Liujunzi Decoction on the basis of the control group. The clinical effect, tumor control rate, and adverse reactions of the two groups were counted;the levels of immune function indexes(CD3 +,CD4 +,CD8 +,CD4 +/CD8 + ) and serum tumor markers [carcinoma embryonic antigen(CEA), carbohydrate antigen 125(CA125), cytokeratin 19 soluble fragment(CYFRA21-1)] were compared between the two groups. Results:The total effective rate was 94.12% in the study group,and 82.35% in the control group,the difference being significant(P<0.05). The tumor control rate was 86.77% in the study group,and 72.06% in the control group,the difference being significant(P<0.05). Before treatment,when compared the levels of CD3+ , CD4+ , CD8+ , and CD4+/CD8+ between the two groups, there was no significance in the difference (P>0.05). After treatment, the levels of CD3 + , CD4 + , and CD4 +/CD8 + in the study group were higher than those in the control group(P<0.05), and the level of CD8 + was lower(P<0.05). After treatment, when compared the levels of CD3 + , CD4+,CD8+,and CD4+/CD8+ before and after treatment in the control group,there was no significance in the difference (P>0.05). After treatment,the levels of CEA,CA125 and CYFRA21- 1 in serum in the two groups were decreased when compared with those before treatment(P<0.05), and the indexes in the study group were lower than those in the control group(P<0.05). The incidence of the damage of the liver and kidney function,hemoglobin reduction,vomiting,diarrhea and abnormal alanine aminotransferase in the study group was lower than that in the control group(P<0.05). Conclusion: The therapy of Daotan tang and Liujunzi tang has defined curative effect in adjuvant chemotherapy of the lung cancer of spleen deficiency with phlegm- dampness type. It can improve the immune function, decrease the levels of CEA, CA125, and CYFRA21-1 in serum,and reduce adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

翁凤钗.导痰汤合六君子汤辅助化疗治疗脾虚痰湿型肺癌临床研究[J].新中医,2021,53(2):96-100

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-01-27
  • 出版日期:
文章二维码